Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.Cell Chemical Biology|July 18, 2020
In Vitro and Cellular Probes to Study PARP Enzyme Target EngagementTim J Wigle, Danielle J Blackwell, Laurie B Schenkel, et al.ACS Medicinal Chemistry Letters|June 24, 2015
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool CompoundLorna H Mitchell, Allison E Drew, Scott A Ribich, et al.Chembiochem : a European Journal of Chemical Biology|April 10, 2021
Targeted Degradation of PARP14 Using a Heterobifunctional Small MoleculeTim J Wigle, Yue Ren, Jennifer R Molina, et al.ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.Journal of Medicinal Chemistry|July 10, 2010
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolinesFeng Liu, Xin Chen, Abdellah Allali-Hassani, et al.ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.Cell Chemical Biology|March 11, 2021
A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explantsLaurie B Schenkel, Jennifer R Molina, Kerren K Swinger, et al.Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.Pageof 6